SFTPA1 sirna

SFTPA1 siRNA (Human)

Cat. Num. AAA8213959

• Gene Names: SFTPA1; SPA; PSAP; PSPA; SP-A; SPA1; PSP-A; SFTP1; SP-A1; COLEC4; SFTPA1B
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: SFTPA1; SFTPA1 siRNA (Human); COLEC4; PSAP; SFTP1; SFTPA; SFTPA1B; Pulmonary surfactant-associated protein A1; PSP-A; PSPA; SP-A; SP-A1; 35 kDa pulmonary surfactant-associated protein; Alveolar proteinosis protein; Collectin-4; SFTPA1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: SFTPA1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 263

• Applicable Applications for SFTPA1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human SFTPA1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for SFTPA1 sirna

siRNA to inhibit SFTPA1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 257467606
• NCBI GeneID: 653509
• NCBI Accession #: NP_001087239.2
• NCBI GenBank Nucleotide #: NM_001093770.2
• UniProt Accession #: Q8IWL2; P07714; Q14DV4; Q5RIR5; Q5RIR7; A8K3T8; B7ZW50; E3VLD8; E3VLD9; E3VLE0; E3VLE1; G5E9J3
• Molecular Weight: 27,736 Da
• NCBI Official Full Name: pulmonary surfactant-associated protein A1 isoform 2
• NCBI Official Synonym Full Names: surfactant protein A1
• NCBI Official Symbol: SFTPA1
• NCBI Official Synonym Symbols: SPA; PSAP; PSPA; SP-A; SPA1; PSP-A; SFTP1; SP-A1; COLEC4; SFTPA1B
• NCBI Protein Information: pulmonary surfactant-associated protein A1
• UniProt Protein Name: Pulmonary surfactant-associated protein A1
• Protein Family: Pulmonary surfactant-associated protein
• UniProt Gene Name: SFTPA1
• UniProt Synonym Gene Names: COLEC4; PSAP; SFTP1; SFTPA; SFTPA1B; PSP-A; PSPA; SP-A; SP-A1
• UniProt Entry Name: SFTA1_HUMAN

NCBI Description

This gene encodes a lung surfactant protein that is a member of a subfamily of C-type lectins called collectins. The encoded protein binds specific carbohydrate moieties found on lipids and on the surface of microorganisms. This protein plays an essential role in surfactant homeostasis and in the defense against respiratory pathogens. Mutations in this gene are associated with idiopathic pulmonary fibrosis. Alternate splicing results in multiple transcript variants. [provided by RefSeq, May 2010]

Uniprot Description

SFTPA1B: In presence of calcium ions, it binds to surfactant phospholipids and contributes to lower the surface tension at the air-liquid interface in the alveoli of the mammalian lung and is essential for normal respiration. Genetic variations in SFTPA1 are a cause of susceptibility to pulmonary fibrosis idiopathic (IPF). Pulmonary fibrosis is a lung disease characterized by shortness of breath, radiographically evident diffuse pulmonary infiltrates, and varying degrees of inflammation and fibrosis on biopsy. It results in acute lung injury with subsequent scarring and endstage lung disease. Genetic variations in SFTPA1 are a cause of susceptibility to respiratory distress syndrome in premature infants (RDS); also known as RDS in prematurity. RDS is a lung disease affecting usually premature newborn infants. It is characterized by deficient gas exchange, diffuse atelectasis, high-permeability lung edema and fibrin-rich alveolar deposits called 'hyaline membranes'. The association between SFTPA1 alleles and respiratory distress syndrome in premature infants is dependent on a variation Ile to Thr at position 131 in SFTPB. Belongs to the SFTPA family.

Protein type: Secreted, signal peptide; Secreted

Chromosomal Location of Human Ortholog: 10q22.3

Cellular Component: proteinaceous extracellular matrix; extracellular space; collagen; extracellular region

Molecular Function: lipid transporter activity; carbohydrate binding

Biological Process: respiratory gaseous exchange; lipid transport

Disease: Pulmonary Fibrosis, Idiopathic